The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax’s COVID-19 vaccine, Nuvaxovid, marking a significant step for the protein-based vaccine. However, the authorization comes with specific usage restrictions setting it apart from the more widely available mRNA vaccines.
According to the FDA, Nuvaxovid is approved for use in adults aged 65 and older, as well as individuals aged 12 to 64 who have certain medical conditions that increase their risk for severe COVID-19. This selective approval reflects a more cautious regulatory stance compared to the broader authorization granted to mRNA vaccines like those from Pfizer-BioNTech and Moderna, which remain widely recommended across age groups.
Novavax’s vaccine uses a traditional protein subunit platform, appealing to those who prefer an alternative to mRNA technology. It works by introducing a harmless version of the virus’s spike protein to trigger an immune response without using genetic material.
Health officials emphasize that the vaccine offers another option for vulnerable populations and may help improve vaccination rates among those hesitant about newer technologies.
Disclaimer: This article is for informational purposes only and does not substitute medical advice. Consult with your healthcare provider to determine the most suitable COVID-19 vaccination option for your individual health needs.
